• Vaccine Name: rBCGMSP1-15
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Vaccine Ontology ID: VO_0004791
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).
• MSP1 from P. yoelii str. 17XNL gene engineering:
  • Type: Recombinant vector construction
  • Description: A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).
  • Detailed Gene Information: Click Here.
• Vector: BCG vaccine vector
  • Vector name: BCG vaccine vector
  • VO vector ID: VO_0001023
• Immunization Route: Intravenous injection (i.v.)

Mouse Response

• Host Strain: C57BL/6, C3H/He, A/J
• Host gender: Female
• Vaccination Protocol: C3H/He mice were immunized intravenously with 10^6 CFU of rBCGMSP1-15 in 200 μl of PBS containing 0.1% PBS-T80. A control group of mice was injected with 106 CFU of BCG in 200 μl of PBS-T80 or PBS-T80 only. 30 days later, the same amount of each sample was injected intraperitoneally to boost the immune response (Matsumoto et al., 1998).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged with 10^4 P. yoelii 17XL-parasitized erythrocytes intravenously or intraperitoneally 1 month after the final immunization (Matsumoto et al., 1998).
• Efficacy: 3 out of 7 mice immunized with GST-MSP1-15 in RAS and 2 out of 8 mice immunized with GST-MSP1-15 in IFA survived the infection. 6 out of 7 mice immunized with rBCGMSP1-15 survived the infection. Data showed the three adjuvants examined are effective for vaccination with MSP1-15, while their efficacy levels differ. The rBCG system was the most effective for vaccination (Matsumoto et al., 1998).